Navigation Links
Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
Date:7/27/2011

SAN DIEGO, July 27, 2011 /PRNewswire/ -- Visionary Pharmaceuticals, Inc., announced today that the company has raised seed round investments from a consortium of Angel Investors. The company is using the capital to develop novel small molecule retinoic acid related orphan receptor (ROR) modulators targeting TH17 T-lymphocytes for the treatment of various autoimmune disorders including rheumatoid arthritis, multiple sclerosis, psoriasis and COPD.

Visionary Pharmaceuticals has created BindingSIGHTs, a proprietary computational technology platform which encompasses an advanced suite of structural biology and chemical informatic tools. BindingSIGHTs enables sophisticated virtual screening and structure-based drug design for challenging molecular drug targets. Visionary Pharmaceuticals has also created the MANIFOLD virtual compound library of more than 22 million compounds, which have been screened against ROR BindingSIGHTs fingerprints. High-scoring drug-like hits have been docked to structural models of the ROR ligand binding site to yield focused compound sets. These compounds are synthesized and screened in cell-based assays providing novel highly ligand-efficient chemical matter to drive structure-based drug discovery.

Visionary Pharmaceuticals has created an innovative drug discovery engine utilizing novel proprietary technology to focus on nuclear hormone receptors. Nuclear hormone receptor modulators represent 15% of all drugs approved in the US and account for more than $27 billion in annual sales. "Our BindingSIGHTs technology and MANIFOLD library enables us to save both time and money in generating the best possible lead series. With the initial seed round investments we are now able to launch full-scale research activities in our state-of-the-art labs," said Gordon Alton, Ph.D., President and CEO of Visionary Pharmaceuticals. "We have assembled a veteran leadership team with proven expertise in driving novel therapies to IND. Additionally, our Board of Directors and Scientific Advisory Board bring us a depth of industry experience in successfully driving high quality drug discovery and development programs and delivering high-value exits. Collectively this experience has resulted in more than a dozen novel drugs either marketed or in clinical trials."

About Visionary Pharmaceuticals

Visionary Pharmaceuticals, Inc. is a privately held drug discovery company focused on new small molecule therapies in inflammation and cancer. Visionary Pharmaceuticals' computational BindingSIGHTs technology and MANIFOLD virtual compound library provides advanced structural biology capabilities to optimize the development of drug candidates. Visionary Pharmaceuticals is currently developing retinoic acid related orphan receptor (ROR) modulators targeting TH17 cells in a variety of diseases. To learn more about Visionary Pharmaceuticals, please visit www.visionarypharmaceuticals.com.

CONTACT:  Gordon Alton, +1-858-335-8120, gordon@visionarypharmaceuticals.com


'/>"/>
SOURCE Visionary Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PreXion, Inc. Names Visionary Industry Leader, Motoaki Saito, M.D., Ph.D. as CEO
2. Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe
3. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
4. Gamma Pharmaceuticals, Inc. Holds Special Shareholders Meeting
5. Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
6. Par Pharmaceutical Companies Announces a Restructuring of Its Branded Division, Strativa Pharmaceuticals, to Maximize Profitability
7. Gamma Pharmaceuticals, Inc. Completes Sale and Books Revenue with National Pharmacy Chain
8. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertaneā„¢ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
9. Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
10. Drs. Ben Machielse Joins Omthera Pharmaceuticals, Inc. as Chief Operating Officer
11. Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):